Seismic Therapeutic, Inc. Unknown
Seismic Therapeutic, Inc. (Nasdaq: Unknown) is a cardio-renal-metabolic drug developer. Its lead program, STX-1150, is in Phase 1 for Elevated LDL-C and increased risk of atherosclerotic cardiovascular disease (ASCVD). Its next catalyst on record is STX-1150: Phase 1 clinical trial ongoing to evaluate safety, tolerability, and LDL-C lowering activity (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: STX-1150 — Phase 1 clinical trial ongoing to evaluate safety, tolerability, and LDL-C lowering activity (date not stated). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| STX-1150 | Elevated LDL-C and increased risk of ASCVD | gene therapy | Phase 1 |
| STX-1200 | Genetically elevated lipoprotein(a) [Lp(a)] and associated cardiovascular risk | gene therapy | Pre-clinical |
| STX-1400 | Familial chylomicronemia syndrome, multifactorial chylomicronemia syndrome, severe hypertriglyceridemia | gene therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.